Business
Eli Lilly Surpasses Quarterly Estimates
Eli Lilly exceeded quarterly financial expectations, raising its revenue outlook to between $85 billion and $87 billion. Sales of Zepbound and Mounjaro drove strong performance.
Coverage timeline — 1 article
CNBC
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.
2026-08-05 10:45 UTC